YaoGeJu

Company directoryChina company filings

Natco Pharma Limited

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference 020b362715

Complete CDE snapshot
2026/11/11 06:42
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/11 06:42.

Drug filings

16 acceptance records as first applicant, grouped into 7 source drug names. Source data as of 2026/11/11 06:42.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Oseltamivir Phosphate Capsules 3 records · Latest accepted 2026/09/28

Import re-registration · 3

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
JYHZ2600247Import re-registration2026/09/28Natco Pharma Limited; Chongqing Huiyan Tongchuang Pharmaceutical Co. LtdCDE ↗
JYHZ2600246Import re-registration2026/09/28Natco Pharma Limited; Chongqing Huiyan Tongchuang Pharmaceutical Co. LtdCDE ↗
JYHZ2600245Import re-registration2026/09/28Natco Pharma Limited; Chongqing Huiyan Tongchuang Pharmaceutical Co. LtdCDE ↗
Doxorubicin Hydrochloride Liposome Injection 4 records · Latest accepted 2024/12/12

Supplement · 4

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
JYHB2400636Supplement2024/12/12Natco Pharma LimitedCDE ↗
JYHB2400635Supplement2024/12/12Natco Pharma LimitedCDE ↗
JYHB2400501Supplement2024/09/25Natco Pharma LimitedCDE ↗
JYHB2400500Supplement2024/09/25Natco Pharma LimitedCDE ↗
Olaparib Tablets 4 records · Latest accepted 2023/06/14

Import · 4

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
JYHS2300075Import2023/06/14Natco Pharma LimitedCDE ↗
JYHS2300074Import2023/06/14Natco Pharma LimitedCDE ↗
JYHS2300054Import2023/04/28Natco Pharma LimitedCDE ↗
JYHS2300053Import2023/04/28Natco Pharma LimitedCDE ↗
Ibrutinib Capsules 1 records · Latest accepted 2023/02/03

Import · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
JYHS2300009Import2023/02/03Natco Pharma LimitedCDE ↗
No verified English name 1 records · Latest accepted 2022/09/08

Import · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
JYHS2200084Import2022/09/08Natco Pharma Limited; Chongqing Kingmed Pharma Co. Ltd.CDE ↗
No verified English name 2 records · Latest accepted 2022/03/31

Not stated by source · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
JTH2200068Not stated by source2022/03/31Natco Pharma Limited; Shandong Hua Bo Kai Sheng Bio Technology Co., Ltd. romanizedCDE ↗
JTH2200044Not stated by source2022/03/04Natco Pharma Limited; Shandong Hua Bo Kai Sheng Bio Technology Co., Ltd. romanizedCDE ↗
Abiraterone Acetate Tablets 1 records · Latest accepted 2021/04/23

Import · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
JYHS2101004Import2021/04/23Natco Pharma Limited; Chongqing Kingmed Pharma Co. Ltd.CDE ↗

Changes in the last 90 days

3 events from 2026/08/14 to 2026/11/11. CDE data as of 2026/11/11 06:42; NMPA data as of 2026/11/10 18:31.

This source was last successfully updated at 2026/11/10 18:31; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Accepted: 3 applications

  1. 2026/09/28Accepted

    Oseltamivir Phosphate Capsules

    JYHZ2600247

    Fact date: 2026/09/28 · Site observation date: 2026/10/22

    View source ↗
  2. 2026/09/28Accepted

    Oseltamivir Phosphate Capsules

    JYHZ2600246

    Fact date: 2026/09/28 · Site observation date: 2026/10/22

    View source ↗
  3. 2026/09/28Accepted

    Oseltamivir Phosphate Capsules

    JYHZ2600245

    Fact date: 2026/09/28 · Site observation date: 2026/10/22

    View source ↗

Under review

3 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/11 06:42.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Oseltamivir Phosphate Capsules JYHZ2600247Import re-registration2026/09/28Natco Pharma Limited; Chongqing Huiyan Tongchuang Pharmaceutical Co. LtdCDE ↗
Oseltamivir Phosphate Capsules JYHZ2600246Import re-registration2026/09/28Natco Pharma Limited; Chongqing Huiyan Tongchuang Pharmaceutical Co. LtdCDE ↗
Oseltamivir Phosphate Capsules JYHZ2600245Import re-registration2026/09/28Natco Pharma Limited; Chongqing Huiyan Tongchuang Pharmaceutical Co. LtdCDE ↗

Catalogue holder records

7 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/11 06:38. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Lanthanum Carbonate Chewable TabletsNatco Pharma LimitedNatco Pharma Limited国药准字HJ202401592024/12/06Generic approved under the new chemical-drug registration classificationCDE ↗
Lanthanum Carbonate Chewable TabletsNatco Pharma LimitedNatco Pharma Limited国药准字HJ202401602024/12/06Generic approved under the new chemical-drug registration classificationCDE ↗
No verified English nameNatco Pharma LimitedNatco Pharma Limited国药准字HJ202301422023/12/05Generic approved under the new chemical-drug registration classificationCDE ↗
Abiraterone Acetate TabletsNatco Pharma LimitedNatco Pharma Limited国药准字HJ202331242023/02/14Generic approved under the new chemical-drug registration classificationCDE ↗
Oseltamivir Phosphate CapsulesNatco Pharma LimitedNatco Pharma Limited国药准字HJ202200242022/03/29Generic approved under the new chemical-drug registration classificationCDE ↗
Oseltamivir Phosphate CapsulesNatco Pharma LimitedNatco Pharma Limited国药准字HJ202200252022/03/29Generic approved under the new chemical-drug registration classificationCDE ↗
Oseltamivir Phosphate CapsulesNatco Pharma LimitedNatco Pharma Limited国药准字HJ202200232022/03/29Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

11 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/11 06:40.

NameCompany / applicantRegistration numberStatusSource update dateView source
No verified English nameNatco Pharma LimitedY20230001170I2024/04/11CDE ↗
No verified English nameNatco Pharma LimitedY20230000557A2025/12/17CDE ↗
No verified English nameNatco Pharma LimitedY20210001103A2025/05/21CDE ↗
No verified English nameNatco Pharma LimitedY20210000875A2024/09/06CDE ↗
No verified English nameNatco Pharma LimitedY20210000058A2025/11/29CDE ↗
No verified English nameNatco Pharma LimitedY20200001143A2025/12/25CDE ↗
No verified English nameNatco Pharma LimitedY20200001144A2023/05/15CDE ↗
No verified English nameNatco Pharma LimitedY20200000836A2024/01/31CDE ↗
No verified English nameNatco Pharma LimitedY20200000894I2020/09/22CDE ↗
No verified English nameNatco Pharma LimitedY20200000242I2020/05/19CDE ↗
No verified English nameNatco Pharma LimitedY20190000441A2023/12/08CDE ↗

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

3 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/11 06:42.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Olaparib Tablets JTH2300049Not stated by source2023/02/16Natco Pharma Limited Pharma Division; Natco Pharma Limited; Rui Di Bo Shi (Beijing) Pharma Co., Ltd. romanizedCDE ↗
Olaparib Tablets JTH2300048Not stated by source2023/02/16Natco Pharma Limited Pharma Division; Natco Pharma Limited; Rui Di Bo Shi (Beijing) Pharma Co., Ltd. romanizedCDE ↗
No verified English name JTH2100057Not stated by source2021/03/01Natco Pharma Limited Chemical Division; Natco Pharma Limited; Guangzhou Bai Rui Pharmaceuticals Co., Ltd. romanizedCDE ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/11 06:42
Chemical-drug catalogue
Last successful update: 2026/11/11 06:38
Full API register
Last successful update: 2026/11/11 06:40
NMPA drug delivery notices
Last successful update: 2026/11/10 18:31 · Current coverage may be incomplete

First index-page publication dates: — to —; 0 pages pending. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Drug names use verified official English names only. Missing names are shown as No verified English name, linking to a Chinese page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized. Original statutory reference numbers are the sole visible Chinese exception.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Chinese free text is not displayed; use the source links or source-name columns in CSV exports.